L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction.
The authors studied the long-term evolution of levodopa-induced dyskinesia (LID) after levodopa challenge in two groups of six STN-deep brain stimulation-treated Parkinson disease (PD) patients, one requiring medication after surgery and the other not. A dramatic (96%) reduction of LID severity was obtained in the six postoperatively untreated patients compared to a moderate improvement (47%) in the treated group (p < 0.03). These data support dopaminergic stimulation and striatal desensitization as major determinants of LID in PD.
Russmann
H
H
Department of Neurology, HUG, Geneva, Switzerland.
Ghika
J
J
Combrement
P
P
Villemure
J G
JG
Bogousslavsky
J
J
Burkhard
P R
PR
Vingerhoets
F J G
FJ
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003342:Corpus Striatum / Q000503:physiopathology; D046690:Deep Brain Stimulation; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000628:therapy*; D011954:Receptors, Dopamine / Q000187:drug effects; D012720:Severity of Illness Index
D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D007980:Levodopa